Factors Associated with Advanced Presentations of Melanoma in the United States from 2004-2015: A National Cancer Database Analysis Cohort Study
Main Article Content
Keywords
melanoma, skin cancer, database, NCDB
Abstract
Purpose: Significant advances have been made in the diagnosis and treatment of melanoma, but mortality remains high. The primary aim of this study was to identify risk factors associated with advanced presentations of melanoma in the US.
Methods and Materials: Stage III and IV melanoma were identified in the National Cancer Database (NCDB) with appropriate staging and pathologic confirmation from 2004-2015. Patient-specific variables were analyzed using chi square and binary logistic regression multivariate analyses to elucidate factors associated with advanced stage melanoma at diagnosis.
Results: There were 477,914 patients meeting inclusion criteria, 63,291 (13.2%) presenting with advanced stage. Factors associated with advanced presentation included lower income, non-Hispanic white race, Medicaid/uninsured insurance, greater distance to treatment centers, male gender, younger age, more medical comorbidities, and southeast U.S. location (p < 0.05, each). All factors were statistically significant on multivariate analysis.
Conclusion: Age, gender, race/ethnicity, geographic location, socioeconomic factors, and distance to treatment center are associated with advanced melanoma diagnosis. Melanoma screening and education should target these groups, and more research is necessary to elucidate causes of the disparities that may preventing the early diagnosis of melanoma for these patients.
References
2. Key Statistics for Melanoma Skin Cancer. https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html. Accessed July 4, 2024.
3. Dawes SM, Tsai S, Gittleman H, Barnholtz-Sloan JS, Bordeaux JS. Racial disparities in melanoma survival. J Am Acad Dermatol. 2016;75(5):983-991. doi:10.1016/j.jaad.2016.06.006.
4. Amini A, Rusthoven CG, Waxweiler TV, et al. Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States. J Am Acad Dermatol. 2016;74(2):309-316. doi:10.1016/j.jaad.2015.09.054.
by histological subtype and race/ethnicity in the United States. J La State Med Soc Off Organ La State Med Soc. 2013;165(4):201-208.
6. Wu X-C, Eide MJ, King J, et al. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006. J Am Acad Dermatol. 2011;65(5, Supplement 1):S26.e1-S26.e13. doi:10.1016/j.jaad.2011.05.034.
7. Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006;166(17):1907-1914. doi:10.1001/archinte.166.17.1907.
8. Byrd-Miles K, Toombs EL, Peck GL. Skin cancer in individuals of African, Asian, Latin-American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians. J Drugs Dermatol JDD. 2007;6(1):10-16.
9. Hu S, Ma F, Collado-Mesa F, Kirsner RS. UV radiation, latitude, and melanoma in US Hispanics and blacks. Arch Dermatol. 2004;140(7):819-824. doi:10.1001/archderm.140.7.819.
10. Hu S, Soza-Vento RM, Parker DF, Kirsner RS. Comparison of stage at diagnosis of melanoma among Hispanic, black, and white patients in Miami-Dade County, Florida. Arch Dermatol. 2006;142(6):704-708. doi:10.1001/archderm.142.6.704.
11. Haque W, Verma V, Butler EB, Teh BS. Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States. J Immunother. 2019;Publish Ahead of Print. doi:10.1097/CJI.0000000000000264.
12. Shi W. Role for radiation therapy in melanoma. Surg Oncol Clin N Am. 2015;24(2):323-335. doi:10.1016/j.soc.2014.12.009.
13. Beaulieu D, Fathi R, Srivastava D, Nijhawan RI. Current perspectives on Mohs micrographic surgery for melanoma. Clin Cosmet Investig Dermatol. 2018;11:309-320. doi:10.2147/CCID.S137513.
14. Richards TB, Johnson CJ, Tatalovich Z, et al. Association between cutaneous melanoma incidence rates among white US residents and county-level estimates of solar ultraviolet exposure. J Am Acad Dermatol. 2011;65(5 Suppl 1):S50-57. doi:10.1016/j.jaad.2011.04.035.
15. Cherobin ACFP, Wainstein AJA, Colosimo EA, Goulart EMA, Bittencourt FV. Prognostic factors for metastasis in cutaneous melanoma. An Bras Dermatol. 2018;93(1):19-26. doi:10.1590/abd1806-4841.20184779.
16. Garcovich S, Colloca G, Sollena P, et al. Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology. Aging Dis. 2017;8(5):643-661. doi:10.14336/AD.2017.0503.
17. Liu-Smith F, Farhat AM, Arce A, et al. Sex differences in the association of cutaneous melanoma incidence rates and geographic ultraviolet light exposure. J Am Acad Dermatol. 2017;76(3):499-505.e3. doi:10.1016/j.jaad.2016.08.027.
18. Davis JL, Buchanan KL, Katz RV, Green BL. Gender differences in cancer screening beliefs, behaviors, and willingness to participate: implications for health promotion. Am J Mens Health. 2012;6(3):211-217. doi:10.1177/1557988311425853.
19. Ward-Peterson M, Acuña JM, Alkhalifah MK, et al. Association Between Race/Ethnicity and Survival of Melanoma Patients in the United States Over 3 Decades: A Secondary Analysis of SEER Data. Medicine (Baltimore). 2016;95(17):e3315. doi:10.1097/MD.0000000000003315.
20. Kooistra L, Chiang K, Dawes S, Gittleman H, Barnholtz-Sloan J, Bordeaux J. Racial disparities and insurance status: An epidemiological analysis of Ohio melanoma patients. J Am Acad Dermatol. 2018;78(5):998-1000. doi:10.1016/j.jaad.2017.11.019.
21. Hu S, Soza-Vento RM, Parker DF, Kirsner RS. Comparison of stage at diagnosis of melanoma among Hispanic, black, and white patients in Miami-Dade County, Florida. Arch Dermatol. 2006;142(6):704-708. doi:10.1001/archderm.142.6.704.
22. Halder RM, Bridgeman-Shah S. Skin cancer in African Americans. Cancer. 1995;75(2 Suppl):667-673. doi:10.1002/1097-0142(19950115)75:2+<667::aid-cncr2820751409>3.0.co;2-i.
23. Hopkins ZH, Moreno C, Carlisle R, Secrest AM. Melanoma prognosis in the United States: Identifying barriers for improved care. J Am Acad Dermatol. 2019;80(5):1256-1262. doi:10.1016/j.jaad.2019.01.003.
24. Adamson AS, Zhou L, Baggett CD, Thomas NE, Meyer A-M. Association of Delays in Surgery for Melanoma With Insurance Type. JAMA Dermatol. 2017;153(11):1106-1113. doi:10.1001/jamadermatol.2017.3338.
25. Tseng WH, Martinez SR. Tumor Location Predicts Survival in Cutaneous Head and Neck Melanoma1. J Surg Res. 2011;167(2):192-198. doi:10.1016/j.jss.2010.10.008.
26. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45(6):613-9. (In eng). DOI: 10.1016/0895-4356(92)90133-8.
27. Rossi M, Pellegrini C, Cardelli L, et al. Familial melanoma: Diagnostic and management implications. Dermatology Practical & Conceptual. 2019;10–16. doi: 10.5826/dpc.0901a03
28. Freedman DM, Sigurdson A, Doody MM, et al. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. Cancer Causes & Control. 2003; 14:847–857. doi: 10.1023/b:caco.0000003839.56954.73
29. Rivera A, Nan H, Li T, et al. Alcohol intake and risk of incident melanoma: A pooled analysis of three prospective studies in the United States. Cancer Epidemiology, Biomarkers & Prevention. 2016;25:1550–1558. doi: 10.1158/1055-9965.epi-16-0303
30. Sample A, He Y. Mechanisms and prevention of UV‐induced melanoma. Photodermatology, Photoimmunology & Photomedicine. 2017; 34:13–24. doi: 10.1111/phpp.12329
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.